Pular para o conteúdo
Doença de músculo rippling
ORPHA:97238CID-10 · G71.8CID-11 · 8C71.YOMIM 606072DOENÇA RARA
Esta doença tem causa genética. Recomendamos procurar um médico geneticista para diagnóstico, exames genéticos e aconselhamento familiar.
MuscularInício infânciaHerança AD/AR

Condição autossômica dominante causada por mutação(ões) no gene CAV3, que codifica a caveolina-3. É caracterizada por contrações dos músculos esqueléticos desencadeadas mecanicamente. A distrofia muscular de cinturas tipo 1C é um distúrbio alélico com um fenótipo sobreposto.

Última verificação: Fonte: sem afirmação sobre o SUS a verificarEm construçãohistóricoSugerir correção
Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

💬
EM LINGUAGEM SIMPLES

A doença de músculo rippling é uma condição genética rara que afeta os músculos esqueléticos, fazendo com que eles tenham contrações visíveis em ondas após serem tocados ou pressionados. Além dessas ondas musculares, quem tem essa condição costuma sentir dor, câimbras e rigidez após fazer exercícios, acompanhadas de fraqueza nos braços ou nas coxas e aumento da panturrilha. A causa está ligada a mutações no gene CAV3, que podem ser herdadas tanto de forma dominante quanto recessiva. No Brasil, a doença não conta com um protocolo PCDT próprio nem remédios específicos fornecidos pelo SUS, mas o sistema público oferece procedimentos como reabilitação e exames genéticos.

📋
Informacoes curadas por IA — podem conter imprecisoes

Condição autossômica dominante causada por mutação(ões) no gene CAV3, que codifica a caveolina-3. É caracterizada por contrações dos músculos esqueléticos desencadeadas mecanicamente. A distrofia muscular de cinturas tipo 1C é um distúrbio alélico com um fenótipo sobreposto.

Publicações científicas
98 artigos
Último publicado: 2025 Aug

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
<1 / 1 000 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Worldwide
Casos conhecidos
59
pacientes catalogados
Início
Adolescent
+ adult, childhood, elderly, infancy
🏥
SUS: Cobertura mínimaScore: 15%
2 procedimentos SIGTAPCID-10: G71.8
🇧🇷Dados SUS / DATASUS
EXAMES E PROCEDIMENTOS RELACIONADOS (2)
•
Sequenciamento completo do exoma (WES)
•
Atendimento em reabilitação — doenças raras
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Características mais comuns

100%prev.
Hipertrofia do músculo da panturrilha
Frequência: 8/8
100%prev.
Concentração elevada de creatina quinase circulante
Frequência: 8/8
100%prev.
Fraqueza muscular proximal
Frequência: 8/8
100%prev.
Sinal de Gowers
Frequência: 4/4
100%prev.
Início juvenil
Frequência: 8/8
25%prev.
Câimbras musculares induzidas por exercício
Frequência: 2/8
14sintomas
Muito frequente (5)
Ocasional (1)
Sem dados (8)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 14 características clínicas mais associadas, ordenadas por frequência.

Frequência: 8/8100%
Concentração elevada de creatina quinase circulanteElevated circulating creatine kinase concentration
Frequência: 8/8100%
Fraqueza muscular proximalProximal muscle weakness
Frequência: 8/8100%
Sinal de GowersGowers sign
Frequência: 4/4100%
Início juvenilJuvenile onset
Frequência: 8/8100%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2025
Total histórico98PubMed
Últimos 10 anos63publicações
Pico202328 papers
Linha do tempo
2025Hoje · 2026📈 2023Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

1 gene identificado com associação a esta condição. Padrão de herança: Autosomal dominant, Autosomal recessive.

CAV3Caveolin-3Disease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (1)
Smooth Muscle Contraction
MECANISMO DE DOENÇA

HyperCKmia

Characterized by persistent elevated levels of serum creatine kinase without muscle weakness.

OUTRAS DOENÇAS (7)
rippling muscle disease 2distal myopathy, Tateyama typelong QT syndrome 9creatine phosphokinase, elevated serum
HGNC:1529UniProt:P56539

Variantes genéticas (ClinVar)

145 variantes patogênicas registradas no ClinVar.

🧬 CAV3: GRCh37/hg19 3p26.3-14.3(chr3:2263690-55016039)x3 ()
🧬 CAV3: GRCh37/hg19 3p26.3-25.3(chr3:61892-10562002)x1 ()
🧬 CAV3: NM_033337.3(CAV3):c.256del (p.Leu86fs) ()
🧬 CAV3: NM_033337.3(CAV3):c.115-1G>T ()
🧬 CAV3: NM_033337.3(CAV3):c.115G>A (p.Val39Met) ()
Ver todas no ClinVar

Vias biológicas (Reactome)

1 via biológica associada aos genes desta condição.

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Doença de músculo rippling

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Pesquisa e ensaios clínicos

Nenhum ensaio clínico registrado para esta condição.

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
26 papers (10 anos)
#1

High-Throughput Immunoassays for Cavin-4 IgG: A Diagnostic Tool for Immune-Mediated Rippling Muscle Disease.

Annals of clinical and translational neurology2025 Apr

Cavin-4 was identified as a potential autoantigen for immune-mediated rippling muscle disease (iRMD). To validate this, we developed and tested various immunoassays, including a cell-based assay (CBA), cavin-4 recombinant protein ELISA, and multi-peptide ELISA. Among 19 iRMD patients, all exhibited muscle rippling, and 13 had percussion-induced mounding. All immunoassays demonstrated clinical and analytical specificities greater than 95%. The protein ELISA had the highest sensitivity (94.7%) and specificity (99.9%), outperforming CBA (sensitivity 89.5%, specificity 99.6%) and the multi-peptide ELISA (sensitivity 79.0%, specificity 97.2%). Our results suggest that the cavin-4 protein ELISA is a promising tool for high-throughput clinical testing in iRMD.

#2

Clinical Phenotype Spectrum in Two Large Chinese Families With Rippling Muscle Disease Caused by CAV-3 c.80G>A.

Neuropathology : official journal of the Japanese Society of Neuropathology2025 Aug

Rippling muscle disease (RMD) is a rare benign myotonic myopathy caused by pathogenic variants in the caveolin-3 (CAV-3) gene and is characterized by highly irritable muscles, transient localized muscle bulges, and ripple-like contractions. There is still a lack of systematic understanding of the phenotypic spectrum of RMD. In this study, clinical data were collected from patients with RMD. The analysis of the pathogenic variants in the CAV-3 gene was conducted by next-generation sequencing and Sanger sequencing. Changes in the expression of the CAV3 protein were analyzed by immunohistochemistry and western blotting. In addition, we performed a literature review of previously reported RMD patients. A total of 12 patients with RMD were clinically diagnosed in two families. All patients presented with childhood-onset exercise intolerance, muscle stiffness, and myalgia after exercise. Percussion-induced rapid muscle mounding and contractions were observed in all patients. Electromyography revealed myogenic damage in Patient 1 and Patient 2. Muscle MRI of the thigh and leg suggested mild muscle atrophy in Patient 2. Muscle pathology revealed nonspecific myopathy-like changes in Patient 2. A heterozygous variant c.80G>A (p.Arg27Gln) in the CAV3 gene was identified in all patients with RMD. Immunohistochemical and western blot analyses revealed reduced expression of the CAV3 protein in muscle tissue. These results demonstrated the clinical, electromyographical, and pathological features of RMD patients in two large Chinese families, with reviewing the literature, provide a better understanding of the variable RMD phenotypes. Trial Registration: SJNKHDJ20221213160659.

#3

Unraveling calcium dysregulation and autoimmunity in immune mediated rippling muscle disease.

Acta neuropathologica communications2025 Jan 16

Rippling Muscle Disease (RMD) is a rare skeletal myopathy characterized by abnormal muscular excitability manifesting with wave-like muscle contractions and percussion-induced muscle mounding. Hereditary RMD is associated with caveolin-3 or cavin-1 mutations. Recently, we identified cavin 4 autoantibodies as a biomarker of immune-mediated RMD (iRMD), though the underlying disease-mechanisms remain poorly understood. Transcriptomic studies were performed on muscle biopsies of 8 patients (5 males; 3 females; ages 26-to-80) with iRMD. Subsequent pathway analysis compared iRMD to human non-disease control and disease control (dermatomyositis) muscle samples. Transcriptomic studies demonstrated changes in key pathways of muscle contraction and development. All iRMD samples had significantly upregulated cavin-4 expression compared to controls, likely compensatory for autoantibody-mediated protein degradation. Proteins involved in muscle relaxation (including SERCA1, PMCA and PLN) were significantly increased in iRMD compared to controls. Comparison of iRMD to dermatomyositis transcriptomics demonstrated significant overlap in immune pathways, and the IL-6 signaling pathway was markedly increased in all iRMD patient muscle biopsies and increased in the majority of iRMD patients' serum. This study represents the first muscle transcriptomic analysis of iRMD patients and dissects underlying disease mechanisms. Increase of sarcolemmal and cellular calcium channels as well as PLN, an inhibitor of the SERCA pump for calcium into the sarcoplasm, likely alters the calcium dynamics in iRMD. These changes in crucial components of muscle relaxation may underlie rippling by altering calcium flux. Our findings provide crucial insights into the differential expression of genes regulating muscle relaxation and highlight potential disease pathomechanisms.

#4

The spectrum of rippling muscle disease.

Muscle &amp; nerve2025 Jan

Rippling muscle disease (RMD) is a rare disorder of muscle hyperexcitability. It is characterized by rippling wave-like muscle contractions induced by mechanical stretch or voluntary contraction followed by sudden stretch, painful muscle stiffness, percussion-induced rapid muscle contraction (PIRC), and percussion-induced muscle mounding (PIMM). RMD can be hereditary (hRMD) or immune-mediated (iRMD). hRMD is caused by pathogenic variants in caveolin-3 (CAV3) or caveolae-associated protein 1/ polymerase I and transcript release factor (CAVIN1/PTRF). CAV3 pathogenic variants are autosomal dominant or less frequently recessive while CAVIN1/PTRF pathogenic variants are autosomal recessive. CAV3-RMD manifests with a wide spectrum of clinical phenotypes, ranging from asymptomatic creatine kinase elevation to severe muscle weakness. Overlapping phenotypes are common. Muscle caveolin-3 immunoreactivity is often absent or diffusely reduced in CAV3-RMD. CAVIN1/PTRF-RMD is characterized by congenital generalized lipodystrophy (CGL, type 4) and often accompanied by several extra-skeletal muscle manifestations. Muscle cavin-1/PTRF immunoreactivity is absent or reduced while caveolin-3 immunoreactivity is reduced, often in a patchy way, in CAVIN1/PTRF-RMD. iRMD is often accompanied by other autoimmune disorders, including myasthenia gravis. Anti-cavin-4 antibodies are the serological marker while the mosaic expression of caveolin-3 and cavin-4 is the pathological feature of iRMD. Most patients with iRMD respond to immunotherapy. Rippling, PIRC, and PIMM are usually electrically silent. Different pathogenic mechanisms have been postulated to explain the disease mechanisms. In this article, we review the spectrum of hRMD and iRMD, including clinical phenotypes, electrophysiological characteristics, myopathological findings, and pathogenesis.

#5

Correction: Unraveling calcium dysregulation and autoimmunity in immune mediated rippling muscle disease.

Acta neuropathologica communications2025 Mar 24

Publicações recentes

Ver todas no PubMed

📚 EuropePMC65 artigos no totalmostrando 61

2025

Clinical Phenotype Spectrum in Two Large Chinese Families With Rippling Muscle Disease Caused by CAV-3 c.80G>A.

Neuropathology : official journal of the Japanese Society of Neuropathology
2025

High-Throughput Immunoassays for Cavin-4 IgG: A Diagnostic Tool for Immune-Mediated Rippling Muscle Disease.

Annals of clinical and translational neurology
2025

Unraveling calcium dysregulation and autoimmunity in immune mediated rippling muscle disease.

Acta neuropathologica communications
2025

The spectrum of rippling muscle disease.

Muscle &amp; nerve
2024

Heat therapy in rheumatic and musculoskeletal diseases - an overview of clinical and molecular effects.

International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
2024

Drug persistence in patients with rheumatic and musculoskeletal diseases during a major economic crisis: results from a nationwide cross-sectional online survey.

Rheumatology international
2023

Stakeholder endorsement advancing the implementation of a patient-reported domain for harms in rheumatology clinical trials: Outcome of the OMERACT Safety Working Group.

Seminars in arthritis and rheumatism
2023

Multimorbidity in rheumatoid arthritis: common mechanistic links and impact and challenges in routine clinical practice.

Rheumatology (Oxford, England)
2023

Generation of two human iPSC lines (HIMRi002-A and HIMRi003-A) derived from Caveolinopathy patients with rippling muscle disease.

Stem cell research
2023

Impact of COVID-19 on disease (self) management and well-being in people with Rheumatic or Musculoskeletal diseases across four European countries: a mixed methods study.

ARP rheumatology
2023

Re-thinking the perception of long-term opioid use in RMDs.

Nature reviews. Rheumatology
2023

Trends in consultations and prescribing for rheumatic and musculoskeletal diseases: an electronic primary care records study.

The British journal of general practice : the journal of the Royal College of General Practitioners
2023

Developing a framework for the implementation of recommendations for lifestyle factors for people with RMDs across Europe: assessment of current materials and implementation needs.

RMD open
2023

Protocol for a systematic literature review of smartphone apps to support the self-management of rheumatic and musculoskeletal diseases: development strategies, theoretical underpinnings and barriers to engagement.

Systematic reviews
2024

Trends for opioid prescribing and the impact of the COVID-19 pandemic in patients with rheumatic and musculoskeletal diseases between 2006 and 2021.

Rheumatology (Oxford, England)
2023

Living with foot and ankle disorders in rheumatic and musculoskeletal diseases: A systematic review of qualitative studies to inform the work of the OMERACT Foot and Ankle Working Group.

Seminars in arthritis and rheumatism
2023

Caveolinopathy: Clinical, histological, and muscle imaging features and follow-up in a multicenter retrospective cohort.

European journal of neurology
2023

Developing a core outcome set for foot and ankle disorders in rheumatic and musculoskeletal diseases: A scoping review and report from the OMERACT 2022 foot and ankle special interest group session.

Seminars in arthritis and rheumatism
2023

The COVID-19 epidemic curve and vaccine acceptance among patients with rheumatic diseases: an ecological study.

Rheumatology international
2023

Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider.

RMD open
2023

Barriers and facilitators for physical activity in rheumatic and musculoskeletal disease: a European-based survey.

Clinical rheumatology
2023

2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice.

Annals of the rheumatic diseases
2023

What Is in the Myopathy Literature?

Journal of clinical neuromuscular disease
2023

Nursing interventions for patients with rheumatic and musculoskeletal diseases on biological therapies: a systematic literature review.

Clinical rheumatology
2023

Coping with rheumatic stressors (CORS) questionnaire: Spanish translation and cross-cultural adaptation.

Journal of patient-reported outcomes
2023

Immune-Mediated Rippling Muscle Disease Associated With Thymoma and Anti-MURC/Cavin-4 Autoantibodies.

Neurology(R) neuroimmunology &amp; neuroinflammation
2023

Immune-mediated rippling muscle disease: not your usual muscle twitches and ache.

Neuromuscular disorders : NMD
2023

Prevalence of undiagnosed rheumatic and musculoskeletal diseases and its association with health-related quality of life and with physical function.

ARP rheumatology
2023

Developing an Outcome Measures in Rheumatology (OMERACT) Core set of Outcome Measures for FOot and ankle disorders in RheumaTic and musculoskeletal diseases (COMFORT): core domain set study protocol.

Trials
2022

NET-RMDs study: networks of fatigue and pain in rheumatic and musculoskeletal diseases - protocol for an international cross-sectional study.

BMJ open
2023

American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 5.

Arthritis &amp; rheumatology (Hoboken, N.J.)
2023

A Mixed-Methods Systematic Review on Syndemics in Rheumatology.

Journal of clinical rheumatology : practical reports on rheumatic &amp; musculoskeletal diseases
2022

Frequency and Pattern of Rheumatoid Arthritis in a Tertiary Hospital in Maiduguri, North-Eastern Nigeria.

West African journal of medicine
2023

Obstetric outcomes in women with rheumatic disease and COVID-19 in the context of vaccination status.

Rheumatology (Oxford, England)
2023

2021 EULAR points to consider to support people with rheumatic and musculoskeletal diseases to participate in healthy and sustainable paid work.

Annals of the rheumatic diseases
2022

[Rippling muscle disease with myasthenia gravis].

Rinsho shinkeigaku = Clinical neurology
2022

Identification of Caveolae-Associated Protein 4 Autoantibodies as a Biomarker of Immune-Mediated Rippling Muscle Disease in Adults.

JAMA neurology
2022

Effects of diet on the outcomes of rheumatic and musculoskeletal diseases (RMDs): systematic review and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs.

RMD open
2022

American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 4.

Arthritis &amp; rheumatology (Hoboken, N.J.)
2022

Exploring discordance between Health Literacy Questionnaire scores of people with RMDs and assessment by treating health professionals.

Rheumatology (Oxford, England)
2022

Involvement of muscle satellite cell dysfunction in neuromuscular disorders: Expanding the portfolio of satellite cell-opathies.

European journal of translational myology
2023

2021 EULAR recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases.

Annals of the rheumatic diseases
2022

EULAR 2021 updated viewpoints on SARS-CoV-2 vaccination in patients with RMDs: a guidance to answer patients' questions.

Annals of the rheumatic diseases
2022

Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry.

Annals of the rheumatic diseases
2021

Neuromuscular hyperexcitability syndromes.

Current opinion in neurology
2022

EULAR points to consider for the use of imaging to guide interventional procedures in patients with rheumatic and musculoskeletal diseases (RMDs).

Annals of the rheumatic diseases
2022

SARS-CoV-2 Infection and COVID-19 Outcomes in Rheumatic Diseases: A Systematic Literature Review and Meta-Analysis.

Arthritis &amp; rheumatology (Hoboken, N.J.)
2022

Rippling Muscle Disease with Irregular Toe Jerks and Anti-acetylcholine Receptor Antibodies: Remission after Extended Thymectomy.

Internal medicine (Tokyo, Japan)
2021

EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs.

Annals of the rheumatic diseases
2020

Immunofluorescence-Based Analysis of Caveolin-3 in the Diagnostic Management of Neuromuscular Diseases.

Methods in molecular biology (Clifton, N.J.)
2019

Peripheral nerve hyperexcitability.

Handbook of clinical neurology
2019

Coexistence of a CAV3 mutation and a DMD deletion in a family with complex muscular diseases.

Brain &amp; development
2018

Teaching Video NeuroImages: Rippling muscle disease with caveolin myopathy.

Neurology
2018

Self-diagnosis of a triple trouble.

Neuromuscular disorders : NMD
2018

Characteristic findings of skeletal muscle MRI in caveolinopathies.

Neuromuscular disorders : NMD
2017

Immune-mediated rippling muscle disease in a patient with treated hypothyroidism.

Journal of the neurological sciences
2017

Caveolin 3 deficiency myopathy associated with dyslipidemia: Treatment challenges and possible pathophysiological association.

Journal of clinical lipidology
2016

Immune-mediated rippling muscle disease and myasthenia gravis.

Journal of neuroimmunology
2016

CAV3 mutations causing exercise intolerance, myalgia and rhabdomyolysis: Expanding the phenotypic spectrum of caveolinopathies.

Neuromuscular disorders : NMD
2016

Mutation in the caveolin-3 gene causes asymmetrical distal myopathy.

Neuropathology : official journal of the Japanese Society of Neuropathology
2015

Caveolinopathies in Greece.

The neurologist
Ver todos os 65 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Doença de músculo rippling.

É de uma associação que acompanha esta doença? Fale com a gente →

Doença com base genética

Um médico geneticista pode ajudar no diagnóstico de Doença de músculo rippling e no aconselhamento genético da família.

Vai consultar um especialista? Confirme o registro dele no conselho.
Conselhos e sociedades

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ordenadas pelo número de sintomas em comum.

Perguntas frequentes

O que as famílias mais perguntam sobre esta doença — cada resposta com a fonte de onde saiu

Respostas geradas por IA a partir das fontes citadas

É uma doença genética rara caracterizada por contrações dos músculos esqueléticos provocadas por estímulos mecânicos ou percussão. Ela está associada a alterações genéticas no gene CAV3, responsável pela proteína caveolina-3.

Referências

Fontes citadas no texto, publicações do grafo e bases de dados usadas neste verbete

5 publicações do grafo RarasNet (PubMed) · 7 bases de dados. Títulos, periódicos e PMIDs vêm direto da fonte, sem intermediação de IA.

  1. ORPHA:97238
    Orphanet
  2. GARD:9164
    GARD (NIH)
  3. Q18966134
    Wikidata

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Citar este verbete

Raras. (s.d.). Doença de músculo rippling. Em Raras — Enciclopédia de Doenças Raras do Brasil. https://raras.org/doenca/doenca-de-musculo-rippling

Formato APA. Conteúdo sob CC BY 4.0 — reuso livre com atribuição.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Compêndio · Raras BR

Doença de músculo rippling

ORPHA:97238 · MONDO:0019947
🇧🇷 Brasil SUS
SIGTAP
2 procedimentos
Geral
Prevalência
<1 / 1 000 000
Casos
59 casos conhecidos
Herança
Autosomal dominant, Autosomal recessive
CID-10
G71.8 · Outros transtornos primários dos músculos
CID-11
Início
Adolescent, Adult, Childhood, Elderly, Infancy
Prevalência
0.0 (Worldwide)
MedGen
UMLS
C1853698
EuropePMC
Wikidata
Papers 10a

📋 Origem dos dados

Esta página agrega dados de fontes públicas e oficiais. Dados sobre cobertura no SUS (PCDT, CEAF) são verificados ativamente por agente proativo (ver badge no infobox). Demais dados têm atribuição de fonte + data da última sincronização — clique para abrir o original.

Doença rara (ontologia)
fonte: Orphanet
Identificador unificado
fonte: MONDO
Genética mendeliana
fonte: OMIM
Indexação biomédica
fonte: MeSH (NLM)
Dado público estruturado
fonte: Wikidata
Rara